Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection

Vitamin D insufficient, HIV+ adults on ART taking D3 50,000 IU twice weekly x5 weeks then 2000 IU daily demonstrated similar repletion success (25OHD >30ng/mL) as historical, HIV- controls. Tenofovir/abacavir were associated with success/failure (respectively) to maintain 25OHD levels post-repletion.

[1]  Christine L. Taylor,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2016, Pediatric Clinical Practice Guidelines & Policies.

[2]  M. LeFevre.  Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. , 2015, Annals of internal medicine.

[3]  Richard D Moore,et al.  Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk , 2013, Vascular health and risk management.

[4]  S. Moe,et al.  Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function: A Randomized, Controlled Trial , 2013, Journal of acquired immune deficiency syndromes.

[5]  E. Fishman,et al.  Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection , 2013, Vascular health and risk management.

[6]  G. Nunnari,et al.  LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. , 2013, European review for medical and pharmacological sciences.

[7]  D. Viswanath,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2012, Pediatrics.

[8]  C. Longenecker,et al.  Vitamin D Supplementation and Endothelial Function in Vitamin D Deficient HIV-Infected Patients: A Randomized Placebo-Controlled Trial , 2012, Antiviral therapy.

[9]  J. Lake,et al.  Vitamin D in HIV-Infected Patients , 2011, Current HIV/AIDS reports.

[10]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  S. Hammer,et al.  Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women , 2011, Osteoporosis International.

[12]  T. Brown,et al.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D , 2010, Antiviral therapy.

[13]  J. Adams,et al.  Update in vitamin D. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  Carlos A Camargo,et al.  Prospective Study of Serum 25‐Hydroxyvitamin D Level, Cardiovascular Disease Mortality, and All‐Cause Mortality in Older U.S. Adults , 2009, Journal of the American Geriatrics Society.

[15]  P. Calabresi,et al.  Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis , 2009, Multiple sclerosis.

[16]  B. Astor,et al.  25-hydroxyvitamin D levels and the risk of mortality in the general population. , 2008, Archives of internal medicine.

[17]  N. Wareham,et al.  Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin Resistance , 2008, Diabetes.

[18]  M. Sääf,et al.  Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. , 2006, AIDS.

[19]  W. Willett,et al.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.

[20]  E. Villamor.  A potential role for vitamin D on HIV infection? , 2006, Nutrition reviews.

[21]  M. Sowers,et al.  Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. , 2004, Diabetes care.

[22]  N. Hariparsad,et al.  Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital , 2004, Journal of clinical pharmacology.

[23]  K. Yarasheski,et al.  HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D , 2003, AIDS.

[24]  D. D. de Luis,et al.  [Relation among micronutrient intakes with CD4 count in HIV infected patients]. , 2002, Nutricion hospitalaria.

[25]  J. Adams,et al.  Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[26]  J. Adams,et al.  Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. , 1999, The Journal of clinical endocrinology and metabolism.

[27]  S. Frøland,et al.  Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  S. Frøland,et al.  Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. , 1994, The Journal of infectious diseases.

[29]  B. Drozdzowska,et al.  Quantitative Ultrasound of Phalanges and Dual-Energy X-ray Absorptiometry of Forearm and Hand in Patients with End-Stage Renal Failure Treated with Dialysis , 1999, Osteoporosis International.